A Phase 1/2, Open-label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of CYC140, an Oral PLK1 Inhibitor, in Subjects With Advanced Solid Tumors and Lymphoma
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 330
- 试验地点
- 5
- 主要终点
- Maximum tolerated dose
研究概览
简要总结
This is a 2-part, phase 1/2, open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, pharmacogenomics, and efficacy of CYC140 administered orally daily. This study consists of Phase 1 and Phase 2 components in subjects with advanced solid tumors and lymphoma who have progressed despite having standard therapy or for which no standard therapy exists.
详细描述
Phase 1 part of the study will consist of a dose-escalation and a dose-finding component.
Phase 2 will enroll subjects with locally advanced, recurrent, or metastatic, histologically confirmed advanced solid tumors or lymphoma, who have failed all standard therapies or for whom standard therapy does not exist, into 8 groups:
Group 1: Bladder cancer
Group 2: Breast cancer: Triple-negative breast cancer (TNBC)
Group 3: Lung cancer (non-small cell lung cancer [NSCLC] and small cell lung cancer [SCLC])
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males or females aged ≥ 18 years.
- •Subjects with histological- or cytological-confirmed, advanced cancer who have progressed on (or not been able to tolerate) standard therapy or for whom no standard anticancer therapy exists
- •For Phase 1, all tumor types may be enrolled
- •For Phase 2, subjects will be enrolled as per the study design section above
- •ECOG performance status of 0-
- •Subjects who relapsed post-autologous or post-allogeneic transplant are eligible. Post-transplant subjects must be without active fungal disease or significant acute graft-versus-host disease
- •Women of childbearing potential (WOCBP) must have a negative pregnancy test (urine or serum) within 7 days prior to starting the study drug. Both males and females must agree to use effective birth control during the study (prior to the first dose and for 6 months after the last dose) if conception is possible during this interval.
- •Subjects must be able to swallow and retain orally administered medication and not have any clinically significant GI abnormalities that may alter the absorption, such as malabsorption syndrome or major resection of the stomach or bowels.
- •Able to agree to and sign the informed consent and to comply with the protocol.
排除标准
- •Subjects with a history of brain metastases or who have signs/symptoms attributable to brain metastases and have not been assessed with radiologic imaging to rule out the presence of brain metastases. Subjects with treated brain metastases that are asymptomatic and have been clinically stable for at least 4 weeks will be eligible.
- •Subjects who have not received vaccines for severe acute respiratory syndrome-corona virus-2 (SARS-COV-2) and have suspected signs and symptoms of the novel coronavirus infection (COVID-19) or have confirmed COVID-
- •Subjects with a history of another primary malignancy, other than:
- •In situ carcinomas, e.g., breast, cervix, and prostate
- •Locally excised nonmelanoma skin cancer
- •No evidence of disease from another primary cancer for 2 or more years and has not taken any anti-cancer treatment in 2 years.
- •Any other clinically significant acute or chronic medical or psychiatric condition or any laboratory abnormality that may increase the risk associated with study drug administration or may interfere with the interpretation of study results.
- •Diseases that significantly affect GI absorption of CYC
- •Subjects who have impaired cardiac function or clinically significant cardiac disease.
- •Presence of active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease) or GI perforation within 6 months of enrollment
- •Presence of an active infection requiring intravenous antibiotics
- •Presence of known history of human immunodeficiency virus-1/2 with uncontrolled viral load and on medications that may interfere with metabolism
- •Presence of active hepatitis B virus (HBV) or hepatitis C virus (HCV).
- •Chemotherapy, biologic therapy, targeted therapy, immunotherapy, extended-field radiotherapy, or investigational agents within 5 half-lives or 3 weeks (whichever is shorter) prior to administration of first dose of study drug on Day 1 or have not recovered from the side effects of such therapy.
- •Major surgery/surgical therapy for any cause within 4 weeks of the first dose
研究组 & 干预措施
Phase 1 Dose Escalation
Phase 1 = CYC140 administered orally in escalating doses starting at 5mg QD M-F week 1 to 3 for 3 weeks of a 4 week cycle. Subsequent cohorts will escalate in dose and schedule until optimized phase 2 dose and schedule is achieved.
干预措施: CYC140 (Drug)
Phase 2
Phase 2 = Recommended CYC140 phase 2 dose and schedule administered orally in 28-day cycles.
干预措施: CYC140 (Drug)
结局指标
主要结局
Maximum tolerated dose
时间窗: 6 months
The incidence rate of dose-limiting toxicities (first cycle only) at each dose level
Overall Response Rate (ORR)
时间窗: 18 months
Assessment of response criteria according to RESIST, Lugano or mSWAT.
次要结局
- Progression-free Survival(24 months)
- Adverse events(24 months)
- T1/2(6 months)
- AUC(6 months)
- Cmax(6 months)
- Overall Survival(24 months)
- Duration of Response(24 months)
- Tmax(6 months)
- Disease Control Rate(24 months)